BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22000992)

  • 1. The expression and role of CXC chemokines in colorectal cancer.
    Verbeke H; Struyf S; Laureys G; Van Damme J
    Cytokine Growth Factor Rev; 2011; 22(5-6):345-58. PubMed ID: 22000992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of proinflammatory cytokines and CXC chemokines (CXCL1-CXCL16) in the progression of prostate cancer: insights on their therapeutic management.
    Ullah A; Jiao W; Shen B
    Cell Mol Biol Lett; 2024 May; 29(1):73. PubMed ID: 38745115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically engineered two-warhead evasins provide a method to achieve precision targeting of disease-relevant chemokine subsets.
    Alenazi Y; Singh K; Davies G; Eaton JRO; Elders P; Kawamura A; Bhattacharya S
    Sci Rep; 2018 Apr; 8(1):6333. PubMed ID: 29679010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of CXC chemokines (CXCL1-CXCL17) in gastric cancer: Prognosis and therapeutic molecules.
    Ullah A; Zhao J; Li J; Singla RK; Shen B
    Life Sci; 2024 Jan; 336():122277. PubMed ID: 37995936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXC Chemokine Receptors in the Tumor Microenvironment and an Update of Antagonist Development.
    Xun Y; Yang H; Li J; Wu F; Liu F
    Rev Physiol Biochem Pharmacol; 2020; 178():1-40. PubMed ID: 32816229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer.
    Cabrero-de Las Heras S; Martínez-Balibrea E
    World J Gastroenterol; 2018 Nov; 24(42):4738-4749. PubMed ID: 30479461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in colorectal cancer: rationale, challenges and potential.
    Ganesh K; Stadler ZK; Cercek A; Mendelsohn RB; Shia J; Segal NH; Diaz LA
    Nat Rev Gastroenterol Hepatol; 2019 Jun; 16(6):361-375. PubMed ID: 30886395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor microenvironment and therapeutic response.
    Wu T; Dai Y
    Cancer Lett; 2017 Feb; 387():61-68. PubMed ID: 26845449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors-A Review of Literature.
    Korbecki J; Kojder K; Kapczuk P; Kupnicka P; Gawrońska-Szklarz B; Gutowska I; Chlubek D; Baranowska-Bosiacka I
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCL5 and CXCL14, but not CXCL16 as potential biomarkers of colorectal cancer.
    Zajkowska M; Dulewicz M; Kulczyńska-Przybik A; Safiejko K; Juchimiuk M; Konopko M; Kozłowski L; Mroczko B
    Sci Rep; 2023 Oct; 13(1):17688. PubMed ID: 37848726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited.
    Dzobo K; Senthebane DA; Dandara C
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of a cuproptosis-related prognostic signature in colon cancer tumor microenvironment and immune responses.
    Xu C; Liu Y; Zhang Y; Gao L
    Front Genet; 2022; 13():928105. PubMed ID: 36313449
    [No Abstract]   [Full Text] [Related]  

  • 13. Associations of C-X-C motif chemokine ligands 1/2/8/13/14 with clinicopathological features and survival profile in patients with colorectal cancer.
    Luo X; Tai J; Zhao Y; Zhao P; Sun D; Wang L
    Oncol Lett; 2022 Oct; 24(4):348. PubMed ID: 36072008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioinformatics Analysis of Prognosis-Related Genes and Expression of CXCL8 in Colorectal Cancer.
    Yao Z; Pan X; Chen W; Pei Y; Chen C; Huang Y; Liu S; Liu Y
    Biomed Res Int; 2022; 2022():3149887. PubMed ID: 35845924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico identification of novel biomarkers for key players in transition from normal colon tissue to adenomatous polyps.
    Isik Z; Leblebici A; Demir Karaman E; Karaca C; Ellidokuz H; Koc A; Ellidokuz EB; Basbinar Y
    PLoS One; 2022; 17(4):e0267973. PubMed ID: 35486660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proliferation of Mouse Prostate Cancer Cells Inflamed by Trichomonas vaginalis.
    Kim SS; Kim KS; Han IH; Kim Y; Bang SS; Kim JH; Kim YS; Choi SY; Ryu JS
    Korean J Parasitol; 2021 Dec; 59(6):547-556. PubMed ID: 34974661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo monitoring of the therapeutic efficacy of a CXCR1/2 inhibitor with 18F-FDG PET/CT imaging in experimental head and neck carcinoma: A feasibility study.
    Montemagno C; Serrano B; Durivault J; Nataf V; Mocquot F; Amblard R; Vial V; Ronco C; Benhida R; Dufies M; Faraggi M; Pagès G
    Biochem Biophys Rep; 2021 Sep; 27():101098. PubMed ID: 34430714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance.
    Khalaf K; Hana D; Chou JT; Singh C; Mackiewicz A; Kaczmarek M
    Front Immunol; 2021; 12():656364. PubMed ID: 34122412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin.
    Cheng Y; Mo F; Li Q; Han X; Shi H; Chen S; Wei Y; Wei X
    Mol Cancer; 2021 Apr; 20(1):62. PubMed ID: 33814009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
    Faruk M; Ibrahim S; Aminu SM; Adamu A; Abdullahi A; Suleiman AM; Rafindadi AH; Mohammed A; Iliyasu Y; Idoko J; Saidu R; Randawa AJ; Musa HS; Ntekim A; Shah KZ; Abubakar S; Adoke KU; Manko M; Awasum CA
    PLoS One; 2021; 16(1):e0245581. PubMed ID: 33465114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.